. availability throughout the world (Bakker et al., 2008; de Kruif 329 et al., 2007; Gogtay et al., 2012; Goudsmit et al., 2006; Muller 330 et al., 2009; Smith et al., 2011). 331 In addition to ensuring the availability of rabies biologics, there 332 is also an urgent need to establish laboratory capacity and national 333 risk assessment systems in regions where surveillance is limited or 334 non-existent (Banyard et al., 2013; Briggs, 2012 ing a single dose (Killian et al., 2009; Miller et al., 2008 and females (Kutzler and Wood, 2006) . 
